Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “NSCLC Patients With EGFR Activating Mutation”

88 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 88 results

Early research (Phase 1)Looking for participantsNCT07755397
What this trial is testing

First in Human Multicenter Open Name Dose-increase, Consolidation Method to Study Safety Drug-level in Blood & Drug Metabolism Clinical Activity of Oral JBI-778 in Lung Cancer Patients With, Without Brain Metastasis IDH Mutated WHO Grade 3,4 Recurrent Glioma, Salivary Glands Tumor

Who this might be right for
NSCLC Patients With EGFR Activating MutationAdenoid Cystic Carcinoma MetastaticAdenoid Cystic Carcinoma of the Head and Neck
Jubilant Therapeutics India Limited 30
Not applicableStudy completedNCT01723878
What this trial is testing

ASPET Study: An Observational Study of Tarceva (Erlotinib) in First Line in Patients With Advanced Non-Small Cell Lung Cancer Harbouring EGFR Activating Mutations

Who this might be right for
Non-Squamous Non-Small Cell Lung Cancer
Hoffmann-La Roche 144
Testing effectiveness (Phase 2)Ended earlyNCT01953926
What this trial is testing

Basket Study of Neratinib in Participants With Solid Tumors Harboring Somatic HER2 or EGFR Exon 18 Mutations

Who this might be right for
Solid Tumors Harboring Somatic HER2 or EGFR Exon 18 Mutations
Puma Biotechnology, Inc. 582
Testing effectiveness (Phase 2)Study completedNCT00411047
What this trial is testing

Gefitinib in Treating Patients With Previously Untreated Stage IIIB or Stage IV Non-Small Cell Lung Cancer

Who this might be right for
Lung Cancer
Massachusetts General Hospital 34
Testing effectiveness (Phase 2)Active Not RecruitingNCT04545710
What this trial is testing

Osimertinib and Abemaciclib in EGFR Mutant Non-Small Cell Lung Cancer After Osimertinib Resistance

Who this might be right for
Lung Cancer
University of California, San Diego 18
Early research (Phase 1)Study completedNCT04959981
What this trial is testing

Anti-Cancer Therapies Targeting the MAPK Pathway in Patients With Advanced NSCLC

Who this might be right for
Advanced Non-squamous Non-small-cell Lung Cancer
Erasca, Inc. 24
Early research (Phase 1)Study completedNCT03516214
What this trial is testing

EGF816 and Trametinib in Patients With Non-small Cell Lung Cancer Harboring Activating EGFR Mutations

Who this might be right for
Bronchial Neoplasms
University of Cologne 18
Large-scale testing (Phase 3)Study completedNCT02759614
What this trial is testing

Compare Bevacizumab in Combination With Erlotinib Versus Erlotinib Alone in NSCLC Patients Activating EGFR Mutations

Who this might be right for
NSCLC
Guangdong Association of Clinical Trials 311
Large-scale testing (Phase 3)Study completedNCT01121393
What this trial is testing

BIBW 2992 (Afatinib) vs Gemcitabine-cisplatin in 1st Line Non-small Cell Lung Cancer (NSCLC)

Who this might be right for
Carcinoma, Non-Small-Cell LungAdenocarcinoma
Boehringer Ingelheim 364
Testing effectiveness (Phase 2)Looking for participantsNCT05948813
What this trial is testing

TY-9591 in the Patients With EGFR Mutations in Advanced NSCLC With Brain Metastases

Who this might be right for
NSCLCEGFR Activating MutationBrain Metastases
TYK Medicines, Inc 420
Post-approval studies (Phase 4)Study completedNCT01609543
What this trial is testing

Tarceva (Erlotinib) in First Line in Patients With Locally Advanced or Metastatic Lung Adenocarcinoma With EGFR Mutations

Who this might be right for
Non-Squamous Non-Small Cell Lung Cancer
Hoffmann-La Roche 62
Testing effectiveness (Phase 2)UnknownNCT03341494
What this trial is testing

EGFR Mutation Positive NSCLC Patients With Gefitinib and Thalidomide

Who this might be right for
NSCLC Stage IVChemotherapy Effect
Fujian Cancer Hospital 128
Testing effectiveness (Phase 2)Ended earlyNCT03805841
What this trial is testing

Study of Tarloxotinib in Pts With NSCLC (EGFR Exon 20 Insertion, HER2-activating Mutations) & Other Solid Tumors With NRG1/ERBB Gene Fusions

Who this might be right for
NSCLC, Stage IVNSCLC Stage IIIBNSCLC, Stage IIIC+5 more
Rain Oncology Inc 41
Testing effectiveness (Phase 2)Study completedNCT04764214
What this trial is testing

SRT for Residual Oligometastases of NSCLC After 3rd Generation EGFR-TKIs

Who this might be right for
NSCLC Stage IVEGFR Activating Mutation
Fudan University 61
Testing effectiveness (Phase 2)Study completedNCT01260181
What this trial is testing

Erlotinib in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer With Epidermal Growth Factor Receptor Mutations

Who this might be right for
Non-Squamous Non-Small Cell Lung Cancer
Hoffmann-La Roche 30
Testing effectiveness (Phase 2)UnknownNCT02319577
What this trial is testing

GEfitinib Plus viNOrelbine in Advanced EGFR Mutated NSCLC. GENOA Trial

Who this might be right for
Non Small Cell Lung Cancer
IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy 80
Testing effectiveness (Phase 2)UnknownNCT01955421
What this trial is testing

Erlotinib 100mg qd Versus Gefitinib 250mg qd for EGFR Mutant Nsclc

Who this might be right for
Advanced Stage Non Small Cell Lung Cancer
Sun Yat-sen University 224
Post-approval studies (Phase 4)Study completedNCT01287754
What this trial is testing

Tarceva (Erlotinib) in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer Who Present EGFR Mutations

Who this might be right for
Non-Small Cell Lung Cancer
Hoffmann-La Roche 24
Testing effectiveness (Phase 2)Looking for participantsNCT06363734
What this trial is testing

Osimertinib Plus Dalpiciclib in Patients With EGFR-mutant, CDK4/6 Pathway Aberrant, Advanced Non-small Cell Lung Cancer Following Acquired Resistance to Third-generation EGFR TKI: a Phase II Trial

Who this might be right for
Non-small Cell Lung CancerEGFR Activating MutationCell Cycle Deregulation+1 more
Tianjin Medical University Cancer Institute and Hospital 32
Large-scale testing (Phase 3)UnknownNCT03074864
What this trial is testing

Targeted Treatment With Intercalated Radiotherapy in EGFR-mutant IIIA/IIIB NSCLC

Who this might be right for
Non-small Cell Lung CancerEpidermal Growth Factor Receptor
Guangdong Provincial People's Hospital 90
Next Page